Cargando…

P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer

The anaplastic lymphoma kinase (ALK) fusion oncogene is observed in 3%–5% of non-small cell lung cancer (NSCLC). Crizotinib and ceritinib, a next-generation ALK tyrosine kinase inhibitor (TKI) active against crizotinib-refractory patients, are clinically available for the treatment of ALK-rearranged...

Descripción completa

Detalles Bibliográficos
Autores principales:	Katayama, Ryohei, Sakashita, Takuya, Yanagitani, Noriko, Ninomiya, Hironori, Horiike, Atsushi, Friboulet, Luc, Gainor, Justin F., Motoi, Noriko, Dobashi, Akito, Sakata, Seiji, Tambo, Yuichi, Kitazono, Satoru, Sato, Shigeo, Koike, Sumie, John Iafrate, A., Mino-Kenudson, Mari, Ishikawa, Yuichi, Shaw, Alice T., Engelman, Jeffrey A., Takeuchi, Kengo, Nishio, Makoto, Fujita, Naoya
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2015
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4739423/ https://www.ncbi.nlm.nih.gov/pubmed/26870817 http://dx.doi.org/10.1016/j.ebiom.2015.12.009

Ejemplares similares

Drug resistance mechanisms in Japanese anaplastic lymphoma kinase‐positive non–small cell lung cancer and the clinical responses based on the resistant mechanisms
por: Yanagitani, Noriko, et al.
Publicado: (2020)

Fibroblast growth factor receptor 3 overexpression mediates ALK inhibitor resistance in ALK‐rearranged non–small cell lung cancer
por: Sakashita, Takuya, et al.
Publicado: (2022)

GSK3 inhibition circumvents and overcomes acquired lorlatinib resistance in ALK-rearranged non-small-cell lung cancer
por: Shimizu, Yuki, et al.
Publicado: (2022)

Prediction of ALK mutations mediating ALK-TKIs resistance and drug re-purposing to overcome the resistance
por: Okada, Koutaroh, et al.
Publicado: (2019)

Clinical efficacy of dacomitinib in rechallenge setting for patients with epidermal growth factor receptor mutant non–small cell lung cancer: A multicenter retrospective analysis (TOPGAN2020‐02)
por: Tanaka, Hisashi, et al.
Publicado: (2022)

Lung Adenocarcinoma with Lynch Syndrome and the Response to Nivolumab
por: Kawashima, Yosuke, et al.
Publicado: (2019)

EGFR T790M mutation after chemotherapy for small cell lung cancer transformation of EGFR-positive non-small cell lung cancer
por: Sonoda, Tomoaki, et al.
Publicado: (2018)

Phase II trial of S‐1 treatment as palliative‐intent chemotherapy for previously treated advanced thymic carcinoma
por: Okuma, Yusuke, et al.
Publicado: (2020)

Phase I Study of Ceritinib (LDK378) in Japanese Patients with Advanced, Anaplastic Lymphoma Kinase-Rearranged Non–Small-Cell Lung Cancer or Other Tumors
por: Nishio, Makoto, et al.
Publicado: (2015)

Clinical efficacy of amrubicin in patients with small cell lung cancer relapse after first‐line treatment including immune checkpoint inhibitors: A retrospective multicenter study (TOPGAN 2021‐01)
por: Uematsu, Shinya, et al.
Publicado: (2022)

Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non–small cell lung cancer
por: Gong, Bo, et al.
Publicado: (2019)

Precision therapy with anaplastic lymphoma kinase inhibitor ceritinib in ALK-rearranged anaplastic large cell lymphoma
por: Subbiah, V., et al.
Publicado: (2021)

Monitoring epidermal growth factor receptor C797S mutation in Japanese non–small cell lung cancer patients with serial cell‐free DNA evaluation using digital droplet PCR
por: Ariyasu, Ryo, et al.
Publicado: (2021)

Barcode sequencing identifies resistant mechanisms to epidermal growth factor receptor inhibitors in circulating tumor DNA of lung cancer patients
por: Kitazono, Satoru, et al.
Publicado: (2019)

Targeting Anaplastic Lymphoma Kinase (ALK) in Rhabdomyosarcoma (RMS) with the Second-Generation ALK Inhibitor Ceritinib
por: van Erp, Anke E. M., et al.
Publicado: (2017)

Ceritinib Treatment for Carcinomatous Meningitis with a Secondary Mutation at I1171T in Anaplastic Lymphoma Kinase
por: Ashinuma, Hironori, et al.
Publicado: (2018)

Microsecond-timescale MD simulation of EGFR minor mutation predicts the structural flexibility of EGFR kinase core that reflects EGFR inhibitor sensitivity
por: Yoshizawa, Takahiro, et al.
Publicado: (2021)

Ceritinib for an anaplastic lymphoma kinase rearrangement-positive patient previously treated with alectinib with poor performance status
por: Kitadai, Rui, et al.
Publicado: (2018)

Dissociated responses at initial computed tomography evaluation is a good prognostic factor in non-small cell lung cancer patients treated with anti-programmed cell death-1/ligand 1 inhibitors
por: Tozuka, Takehiro, et al.
Publicado: (2020)

The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models
por: Katayama, Ryohei, et al.
Publicado: (2019)

Prognostic value of (18)F‐fluoroazomycin arabinoside PET/CT in patients with advanced non‐small‐cell lung cancer
por: Saga, Tsuneo, et al.
Publicado: (2015)

Phase II study of ceritinib in alectinib‐pretreated patients with anaplastic lymphoma kinase‐rearranged metastatic non‐small‐cell lung cancer in Japan: ASCEND‐9
por: Hida, Toyoaki, et al.
Publicado: (2018)

Real-World Outcome Analysis of Patients With Stage IV NSCLC Treated With Tyrosine Kinase and Immune Checkpoint Inhibitors
por: Ariyasu, Ryo, et al.
Publicado: (2023)

Efficacy and safety of ceritinib in anaplastic lymphoma kinase‐rearranged non‐small cell lung cancer: A systematic review and meta‐analysis
por: Tian, Wei, et al.
Publicado: (2020)

ACT-01 THE SECOND GENERATION ANAPLASTIC LYMPHOMA KINASE (ALK) INHIBITOR CERITINIB EFFECTIVELY INDUCES CELL DEATH IN HUMAN GLIOBLASTOMA CELLS
por: Kawauchi, Daisuke, et al.
Publicado: (2019)

Soluble PD-L1 works as a decoy in lung cancer immunotherapy via alternative polyadenylation
por: Sagawa, Ray, et al.
Publicado: (2022)

Cost-Effectiveness Analysis Of Ceritinib And Alectinib Versus Crizotinib In The Treatment Of Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer
por: Liu, Maobai, et al.
Publicado: (2019)

Safety and Activity of the Combination of Ceritinib and Dasatinib in Osteosarcoma
por: Beck, Olaf, et al.
Publicado: (2020)

Front‐line treatment of ceritinib improves efficacy over crizotinib for Asian patients with anaplastic lymphoma kinase fusion NSCLC: The role of systemic progression control
por: Huang, Shih‐Hao, et al.
Publicado: (2019)

Cost-effectiveness of ensartinib, crizotinib, ceritinib, alectinib, brigatinib and lorlatinib in patients with anaplastic lymphoma kinase-positive non-small cell lung cancer in China
por: Luo, Xia, et al.
Publicado: (2022)

Clinical influence of switching companion diagnostic tests for EGFR‐TKs from Therascreen to Cobas v2
por: Uchibori, Ken, et al.
Publicado: (2021)

Characteristics of central nervous system progression in non‐small cell lung cancer treated with crizotinib or alectinib
por: Sakamoto, Hiroaki, et al.
Publicado: (2021)

Distinct Characteristics of Small Cell Lung Cancer Correlate With Central or Peripheral Origin: Subtyping Based on Location and Expression of Transcription Factor TTF-1
por: Miyauchi, Eisaku, et al.
Publicado: (2015)

Acute Interstitial Lung Disease Induced by Rechallenge with Ceritinib
por: Hotta, Takamasa, et al.
Publicado: (2019)

Ceritinib in Japanese patients with anaplastic lymphoma kinase (ALK)+ non-small cell lung cancer: interim analysis results of a post-marketing surveillance study
por: Kaneda, Hiroyasu, et al.
Publicado: (2020)

Clinical characteristics of patients with KRAS mutation detected by liquid biopsy
por: Amino, Yoshiaki, et al.
Publicado: (2023)

Feasibility of next‐generation sequencing test for patients with advanced NSCLC in clinical practice
por: Ariyasu, Ryo, et al.
Publicado: (2020)

In vitro and in vivo synergistic efficacy of ceritinib combined with programmed cell death ligand‐1 inhibitor in anaplastic lymphoma kinase‐rearranged non‐small‐cell lung cancer
por: Du, Ping, et al.
Publicado: (2020)

Cost-effectiveness analysis of ceritinib vs. crizotinib in previously untreated anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) in Hong Kong
por: Loong, Herbert H., et al.
Publicado: (2020)

A retrospective study of alectinib versus ceritinib in patients with advanced non–small-cell lung cancer of anaplastic lymphoma kinase fusion in whom crizotinib treatment failed
por: Kuo, Chih-Hsi Scott, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_md8sv6f5t5924kk8ndtb0q1e68